Active surveillance using carefully defined criteria can reduce the burden of therapy in patients with slow developing disease, while providing definitive therapy for all those with more aggressive disease. Active surveillance is typically offered to men with slow-growing prostate cancer that may not progress of their lifetime. Basically, the cancer is not likely to be fatal and treatment may cause unnecessary adverse effects. Patients on energetic surveillance undergo periodic screenings to determine disease progression or risk. This abstract represents data from the next phase of the scholarly study, which was initiated in 1995. Since then, researchers have studied 453 active surveillance candidates to determine the greatest intervention parameters .23andMe, Pfizer jointly launch Lupus Research Study 23andMe, Inc., the leading personal genetics company, announced the launch of the Lupus STUDY in collaboration with Pfizer Inc today. The ongoing companies aim to enroll 5,000 individuals with systemic lupus erythematosus, even more known as lupus commonly, into the scholarly study to greatly help better understand the genetics of lupus. The effort can be in collaboration with the Lupus Research Institute, and in concert with Lupus Awareness Month in May. 1 Approximately.5 million people in the U.S. Suffer from lupus, an autoimmune disease in which the immune system can attack the standard, healthy tissues of your body almost anywhere.